22–23 Jul 2026
Heidelberg Congress Center
Europe/Berlin timezone

Predictors of Adherence in a Personalized Lung Cancer Exercise Trial: Results from the PEP Study

23 Jul 2026, 11:45
1h 15m
Heidelberg Congress Center ( Heidelberg Congress Center )

Heidelberg Congress Center

Heidelberg Congress Center

Czernyring 20 69115 Heidelberg Germany
1 - Scientific Poster Poster Session

Speaker

Victoria Bandera (University of Utah Huntsman Cancer Institute)

Description

Background: Exercise programs benefit lung cancer patients undergoing surgery but are rarely incorporated into clinical practice. Predictors of adherence to a perioperative remotely delivered, pragmatic, and personalized exercise intervention in lung cancer patients were assessed.
Methods: Patients randomized to the exercise group in the Precision Exercise Prescription (PEP) Study were included in the analyses. The exercise intervention was tailored to patients’ mobility starting in the pre-surgery period. Weekly Motivation And Problem-Solving (MAPS) calls were conducted for motivational purposes and to discuss barriers, exercise modifications, and self-reported exercise adherence with participants. Median scores derived from MAPS call notes were used to classify patients as non- (1: no activity) or partially (2: <3 days/week) vs. fully adherent (3: 3 or more days/week) from pre-surgery to 2 months and 2–6 months post-surgery. We investigated baseline predictors, clinicodemographic characteristics, 6-minute walk test (6MWT) distance, fatigue (FACIT-F), and quality of life (FACT-L), using forward stepwise logistic regression models.
Results: From baseline to 2-months, 41% of participants were fully adherent (N=34), 50% were partially-adherent (N=41) and 9% of participants were non-adherent (N=7). During the 2-to-6-month timeframe, 33% of participants were fully adherent (N=23), 61% were partially-adherent (N=42), and 6% of participants were non-adherent (N=4). From 2-6 months, fully adherent patients were older (69±9 years vs. 62±15 years) and had primary vs. secondary lung cancer diagnoses (96% vs. 70%) relative to non/partially-adherent patients. Baseline fatigue (OR:0.93, 95%CI:0.86–0.99, p=0.04) and secondary lung cancer (OR:0.11, 95%CI:0.01–0.63, p=0.04) were significant predictors of adherence for 2-6-month timeframe. Fatigue remained a significant predictor after adjusting for age, cancer type, and body mass index (OR: 0.92, 95%CI: 0.85–0.99, p=0.03). No significant predictors emerged for baseline to 2 months post-surgery.
Conclusions: Adherence to the PEP Study intervention was greater among older, primary lung cancer patients with lower fatigue at baseline.

Keywords

Adherence, intervention, randomized clinical trial, lung cancer

Abstract submitters declaration yes
Conflict of Interest & Ethical Approval yes

Author

Victoria Bandera (University of Utah Huntsman Cancer Institute)

Co-authors

Dr Caroline Himbert (University of Utah Huntsman Cancer Institute) Bailee Daniels (Huntsman Cancer Institute) Christopher Barnes (University of Utah Huntsman Cancer Institute) Dr Kenneth Boucher (University of Utah, Huntsman Cancer Institute) Dr Kelly Lundberg (University of Utah) Dr Brian Mitzman (University of Utah Huntsman Cancer Institute) Dr Rachel Hess (University of Utah) Dr Jaewhan Kim (University of Utah Huntsman Cancer Institute) Dr Jennifer Ligibel (Dana-Farber Cancer Institute and Harvard Medical School) Dr Adriana Coletta (University of Utah Huntsman Cancer Institute) Dr Robin Marcus (University of Utah) Dr David Wetter (University of Utah Huntsman Cancer Institute) Dr Paul LaStayo (University of Utah) Dr Thomas Varghese Jr (University of Utah Huntsman Cancer Institute) Dr Cornelia Ulrich (University of Utah Huntsman Cancer Institute)

Presentation materials

There are no materials yet.